[{"data":1,"prerenderedAt":25},["ShallowReactive",2],{"$fkxAK2d-QsnpB7ay6Fge3xZu8alI4ordlaFZH1Uwx4oI":3},{"card":4,"examId":6,"chapterTitle":22,"prev":23,"next":24},{"id":5,"examId":6,"prompt":7,"answer":8,"choices":9,"questionType":14,"explanation":15,"explanationDetail":16,"mistakeHint":16,"lectureRef":16,"storyRef":16,"chapterSlug":17,"sectionCode":18,"sectionTitle":19,"clusterSlug":20,"term":16,"sequenceOrder":16,"regionWeight":16,"revisionMark":16,"isActive":21},"ch5-048","touhan","副作用等報告の送付手段として認められていないのはどれか。",3,[10,11,12,13],"郵送","ファクシミリ","電子メール","口頭（電話）のみ","four","報告書の送付方法は、郵送・ファクシミリ・電子メールのほか、令和3年4月からはウェブサイトへの直接入力による電子的報告も可能になりました。口頭（電話）のみでの報告は認められていません。",null,"chapter-5","5-II-2","副作用情報等の評価及び措置","fukusayou-hyouka",true,"第5章 医薬品の適正使用・安全対策","ch5-047","ch5-049",1784619074271]